Two anti-amyloid biologics with 27–35% cognitive slowing are approved, but CMS amyloid confirmation and ARIA monitoring requirements constrain the 6.7 million eligible US patients.
Two anti-amyloid monoclonal antibodies have received full FDA approval for early symptomatic Alzheimer's Disease: lecanemab (Leqembi, Eisai/Biogen, full approval July 2023) and donanemab (Kisunla, Eli Lilly, full approval July 2024). The CLARITY AD trial demonstrated 27% slowing of cognitive decline (CDR-SB) at 18 months for lecanemab; TRAILBLAZER-ALZ 2 demonstrated 35% slowing for donanemab in the combined low-medium tau population. Both require confirmed amyloid pathology (PET or CSF) and are indicated for the mild cognitive impairment (MCI) or mild dementia stage.
CMS covers lecanemab under Medicare Part B as an administered infusion, conditional on confirmed amyloid pathology and physician-supervised data collection. Amyloid PET coverage under Medicare was historically limited (beta-amyloid PET NCD restricted to once per lifetime, one indication). Blood-based biomarkers (plasma pTau-217) are emerging as lower-cost amyloid confirmation tools. Amyloid-related imaging abnormalities (ARIA), a class effect requiring serial MRI monitoring, add infrastructure cost and constrain eligible infusion sites.
Approved Alzheimer's Disease disease-modifying therapies — United States, 2024
| Drug (Brand / INN) | Mechanism | Company | US Approval | Key Trial Result | CMS Coverage / Routing |
|---|---|---|---|---|---|
| Leqembi (lecanemab) | Anti-amyloid-beta mAb IV | Eisai / Biogen | Jul 2023 (full) | CLARITY AD: 27% CDR-SB slowing at 18 months vs placebo | Medicare Part B (infusion); amyloid confirmation required; data collection required |
| Kisunla (donanemab) | Anti-amyloid-beta mAb IV | Eli Lilly | Jul 2024 (full) | TRAILBLAZER-ALZ 2: 35% CDR-SB slowing (low-medium tau population) vs placebo | CMS coverage review in progress post-approval; expected Part B infusion coverage |
| Namzaric / Aricept (memantine / donepezil) | NMDA antagonist + AChE inhibitor oral | Allergan / Eisai | 2003–2014 | Symptomatic benefit only; no disease modification; widely generic | Part D; generic pricing; no prior auth barrier |
Sources: FDA Drugs@FDA (approval dates); NEJM CLARITY AD (PMID 36449413); JAMA TRAILBLAZER-ALZ 2 (PMID 37459141); CMS NCD 200.3 (anti-amyloid mAb, 2023 update); Eisai WAC announcement Jun 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • CMS NCD language for anti-amyloid monoclonal antibodies post-full-approval (2023–2024 updates) • Amyloid PET vs CSF confirmation criteria and once-per-lifetime PET coverage limitations • Data collection and registry requirements for eligible infusion sites • ApoE4 genotyping and ARIA monitoring obligations by product label
Delivers
- • Head-to-head efficacy comparison: CDR-SB slowing at 18 months (CLARITY AD vs TRAILBLAZER-ALZ 2) • ARIA incidence and severity comparison: ARIA-E and ARIA-H rates and clinical implications by ApoE4 status • Dosing schedule: bi-weekly (lecanemab) vs monthly (donanemab) infusion and amyloid clearance endpoint • WAC comparison: Leqembi $26,500 vs Kisunla $32,000 annual list price and Part B reimbursement rates
Delivers
- • Phase 3 readout timelines: remternetug (Roche), trontinemab (Roche), ALZ-801 oral (AZTherapies) • Mechanism differentiation: tau vs amyloid targeting and implications for combination therapy • Oral agent pipeline (ALZ-801): commercial threat to infusion-based market if Phase 3 positive • Biomarker landscape: pTau-217 blood test readiness and impact on patient identification at scale
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why 6.7 million US Alzheimer's patients narrows sharply once confirmed amyloid pathology via PET or CSF becomes the gating step.
- How once-per-lifetime Medicare PET coverage and emerging plasma pTau-217 blood tests reshape who gets identified for treatment.
- Why donanemab's 35% CDR-SB slowing in TRAILBLAZER-ALZ 2 outpaces lecanemab's 27% result from CLARITY AD at 18 months.
- How Kisunla's $32,000 annual list price and monthly dosing compare against Leqembi's $26,500 price and bi-weekly infusion schedule.
- Why ARIA, a class effect across both anti-amyloid antibodies, forces serial MRI monitoring that constrains which infusion sites qualify.
- How ApoE4 genotyping requirements and product-label monitoring obligations add infrastructure cost beyond the infusion itself.
- Why Medicare Part B coverage for lecanemab requires confirmed amyloid pathology plus physician-supervised data collection at the infusion site.
- How donanemab's CMS coverage review, still in progress post-approval, compares to lecanemab's existing Part B pathway.
- Why the once-per-lifetime Medicare limit on amyloid PET scans pushes payers toward blood-based pTau-217 confirmation instead.
- How CSF and PET confirmation pathways compare in cost and access as plasma pTau-217 testing scales nationally.
- Why Roche's remternetug and trontinemab, alongside oral candidate ALZ-801, could disrupt the infusion-based market by 2027.
- How an oral agent like ALZ-801 threatens to displace bi-weekly and monthly infusion regimens if Phase 3 succeeds.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US Alzheimer's Disease Competitive Intelligence sources: FDA Drugs@FDA (approval dates and labels), primary trial publications (NEJM CLARITY AD, JAMA TRAILBLAZER-ALZ 2), CMS NCD 200.3 and subsequent policy updates, ClinicalTrials.gov pipeline registrations, and Alzheimer's Association 2023 Facts and Figures.
- Drug approval dates and label indications verified against FDA Drugs@FDA database (lecanemab full approval Jul 2023; donanemab full approval Jul 2024)
- CLARITY AD trial results verified against NEJM primary publication (PMID 36449413)
- TRAILBLAZER-ALZ 2 trial results verified against JAMA primary publication (PMID 37459141)
- CMS coverage criteria for lecanemab verified against CMS NCD 200.3 and subsequent Medicare coverage policy update (2023)
Frequently asked questions
Commission this brief
AXLRx delivers US Alzheimer's Disease competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.